Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
X-396 in ROS1-positive NSCLC (Phase II, single-arm, China)
CTR20180400Phase 2Suspended
- Sponsor
- Beta Pharma
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ensartinib in non-small cell lung cancer (NSCLC), sponsored by Beta Pharma. Started Apr 2018; status: suspended.
02
Drugs
ensartinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20180400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180400.